Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Unveils Positive Phase II Results For Genetic Auto-inflammatory Disease Candidate

This article was originally published in The Pink Sheet Daily

Executive Summary

Interleukin 1b blocker ACZ885 achieves complete clinical remission in seven days for Cryopyrin-Associated Periodic Syndrome Patients.

You may also be interested in...



Novartis Moves Up First Filing For Auto-Inflammatory Drug ACZ885 In Cryopyrin-Associated Syndromes

Canakinumab showcases Novartis Institute for Biomedical Research’s novel subpopulaton proof-of-concept model.

Novartis Moves Up First Filing For Auto-Inflammatory Drug ACZ885 In Cryopyrin-Associated Syndromes

Canakinumab showcases Novartis Institute for Biomedical Research’s novel subpopulaton proof-of-concept model.

Drug Development Chief Departs Beleaguered Novartis

Trevor Mundel is set to replace James Shannon, Novartis confirms to “The Pink Sheet” DAILY.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067713

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel